Duration of the antihistaminic effect after discontinuation of ebastine

被引:8
作者
Frossard, N
Vital-Durand, D
Mounedji, N
Valleteau, A
机构
[1] INSERM U425, F-67401 Illkirch Graffenstaden, France
[2] Aventis, Montrouge, France
[3] Ctr Hosp Lyon Sud, ART, F-69495 Pierre Benite, France
关键词
allergy; antihistamine; ebastine; histamine challenge; skin prick test;
D O I
10.1034/j.1398-9995.2001.056006553.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The inhibitory effect of antihistamines on allergen-induced skin reactions can impair the results of allergen skin testing, which are necessary for the diagnosis of atopic diseases. This study was designed to determine the time period required for the inhibitory effect of ebastine on allergen-induced skin reactivity to disappear completely. Methods: This was a double-blind, placebo-controlled, parallel-group study including 23 out of 27 randomized patients. They received either ebastine 20 mg or placebo once daily for 7 days. At the end of treatment, allergen challenge was performed daily for 7 days. Histamine challenge was performed on day 1 (6 and 24 h) and day 5 after treatment. The wheal and flare surface areas were measured and analyzed. Results: Highly significant inhibition of the wheal and flare response induced by allergen was observed after ebastine treatment on days 1 and 2 as compared with placebo (P <0.01 for both). The inhibition was reduced, although still significant, by day 3 (P <0.05). No significant difference was observed by day 4 between the ebastine and the placebo groups. The effects of histamine challenge were significantly reduced in the ebastine compared with the placebo group at day 1 (6 and 24 h), and were similar at day 5 after treatment. Conclusions: Our results show that the wheal and flare response to allergen after ebastine discontinuation returns to placebo values after 4 days. Therefore, patients using ebastine need to be antihistamine-free for 4 days before the skin prick test. This is valuable information for the allergologist seeking to diagnose allergen sensitivity.
引用
收藏
页码:553 / 557
页数:5
相关论文
共 22 条
[1]   DURATION OF THE INHIBITORY ACTIVITY ON HISTAMINE-INDUCED SKIN WEALS OF SEDATIVE AND NON-SEDATIVE ANTIHISTAMINES [J].
ALMIND, M ;
DIRKSEN, A ;
NIELSEN, NH ;
SVENDSEN, UG .
ALLERGY, 1988, 43 (08) :593-596
[2]  
Bousquet J, 1998, CLIN EXP ALLERGY, V28, P49
[3]   A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis [J].
Bousquet, J ;
Gaudaño, EM ;
Carlos, AGP ;
Staudinger, H .
ALLERGY, 1999, 54 (06) :562-568
[4]   Comparison of the efficacy of ebastine 10mg and 20mg once daily with that of cetirizine 10mg once daily in adults with seasonal allergic rhinitis - A multicentre double-blind study [J].
Cohen, B ;
Gehanno, P .
DRUGS, 1996, 52 :26-29
[5]   Efficacy and tolerability comparison of ebastine 10 and 20mg with loratadine 10mg - A double-blind, randomised study in patients with perennial allergic rhinitis [J].
Davies, RJ .
CLINICAL DRUG INVESTIGATION, 1998, 16 (06) :413-420
[6]   PRECISION OF SKIN PRICK AND PUNCTURE TESTS WITH 9 METHODS [J].
DEMOLY, P ;
BOUSQUET, J ;
MANDERSCHEID, JC ;
DREBORG, S ;
DHIVERT, H ;
MICHEL, FB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 88 (05) :758-762
[7]   Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers [J].
Frossard, N ;
Benabdesselam, O ;
Purohit, A ;
Mounedji, N ;
Pauli, G .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2000, 14 (04) :409-413
[8]   Consistency of the efficacy of cetirizine and ebastine on skin reactivity [J].
Frossard, N ;
Melac, M ;
Benabdesselam, O ;
Pauli, G .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 80 (01) :61-65
[9]   THE EFFECTS OF ASTEMIZOLE, CETIRIZINE AND LORATADINE ON THE TIME COURSE OF WEAL AND FLARE REACTIONS TO HISTAMINE, CODEINE AND ANTIGEN [J].
HUMPHREYS, F ;
HUNTER, JAA .
BRITISH JOURNAL OF DERMATOLOGY, 1991, 125 (04) :364-367
[10]   Ebastine - An update of its use in allergic disorders [J].
Hurst, M ;
Spencer, CM .
DRUGS, 2000, 59 (04) :981-1006